A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2017
At a glance
- Drugs TPIV 200 (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 12 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 12 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 31 Aug 2017 According to a TapImmune media release, this study will benefit from FDA Fast Track and Orphan Drug designation